BOSTON, Mass. — Inozyme Pharma, Inc. (Nasdaq: INZY), a clinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of pathologic mineralization and intimal proliferation, today announced that it will host a conference call and webcast on Monday, April 8, 2024 at 8:00 a.m. Eastern Time. During the conference...
treatment News
Okayama, Japan – Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disease characterized by progressive loss of motor functions, which eventually leads to death within 5 years of its onset. This disease causes weakness and atrophy of limbs and other muscles, which affect mobility speech, eating, and even breathing in patients....
Hong Kong – Artificial intelligence is a growing presence in biopharma, with applications beyond the discovery apparatus. It was a hot-button issue in San Francisco last week as the industry gathered around the annual JP Morgan Healthcare Conference. Eli Lilly and Novartis even announced multi-million-dollar discovery deals with Alphabet’s Isomorphic...
Rockville, Maryland – Insilico Medicine, a generative artificial intelligence (AI)-driven clinical-stage biotechnology company, today announced that the company has initiated the first-in-human study for ISM5411, a potentially first-in-class poly hydroxylase domain (PHD) 1/2 inhibitor for the treatment of inflammatory bowel disease (IBD). Designed and developed by Insilico’s proprietary end-to-end AI...
CAMBRIDGE, Mass. — Insilico Medicine (“Insilico”), a clinical-stage generative artificial intelligence (AI)-driven biotechnology company, today announced positive topline results from the Phase IIa trial of ISM001-055, the novel drug candidate developed in-house using generative AI to target TNIK (Traf2- and NCK- interacting kinase) for the treatment of idiopathic pulmonary fibrosis...
Hong Kong – Insilico Medicine, a clinical stage generative artificial intelligence (AI)-driven drug discovery company, recently published an early research that it has identified MYT1 as a promising new therapeutic target for breast and gynecological cancer, and discovered a series of novel, potent, and highly selective inhibitors specifically targeting MYT1....
CAMBRIDGE, Mass. — Insilico Medicine, a clinical-stage generative AI-driven biotechnology company, today announced ISM6331, potential best-in-class pan-TEAD inhibitor, has received the U.S. Food and Drug Administration (FDA) Investigational New Drug (IND) clearance for the treatment of mesothelioma, following the grant of Orphan Drug Designation (ODD) in June 2024. It brings...
Cambridge, MA, Sept 18, 2024 – Insilico Medicine, a clinical-stage generative AI-driven drug discovery company, announced positive preliminary results from its Phase IIa clinical trial evaluating ISM001-055. ISM001-055 is a first-in-class small molecule targeting TNIK (Traf2- and Nck-interacting kinase) and was designed utilizing generative AI to treat idiopathic pulmonary fibrosis...
BRIDGEWATER, N.J — Insmed Incorporated (Nasdaq: INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced positive topline results from the ASPEN study, a global, randomized, double-blind, placebo-controlled Phase 3 study to assess the efficacy, safety, and tolerability of...
JUPITER, Fla. — Like the Greek mythological beast with a snake’s tail and two ferocious heads, a potential Parkinson’s medicine created in the lab of chemist Matthew Disney, Ph.D., is also a type of chimera bearing two heads. One seeks out a key piece of Parkinson’s-causing RNA, while the other...